|Day Low/High||31.97 / 32.04|
|52 Wk Low/High||10.26 / 32.12|
AstraZeneca said Friday that it had received a second "complete response letter" from the U.S. FDA regarding its Hyperkalaemia treatment, putting the drug's approval process in the United States doubt.
Both pharma companies are promising names that easily could become buyout targets.
Relypsa's (RLYP) stock rating was lowered to 'hold' from 'buy' at Stifel on Monday.
The most recent short interest data has been released for the 07/29/2016 settlement date, which shows a 6,916,160 share decrease in total short interest for Relypsa, Inc , to 9,368,893, a decrease of 42.47% since 07/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.
The sector seems to be rebounding after tumbling by more than 40%.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Morgan Stanley believes these stocks will have negative earnings catalysts, but how does the technical analysis stack up?
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Relypsa, Inc.
Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
Shares of Relypsa surged on news of a takeover by Galenica, the owner of Switzerland's biggest pharmacy network.
Rigrodsky & Long, P.A.
Shares of Relypsa are rallying after the company announced it has agreed to be acquired by Galenica Group in a $1.53B deal.
Relypsa (RLYP) stock is up in early morning trading on Thursday after Galenica agreed to purchase the biotech for $1.53 billion.
General Motors crushed Wall Street earnings estimates before the opening bell.
The Swiss buyer will gain better U.S. access and drugs including Veltassa, which treats high blood potassium levels.
After a big run-up, the market behaved in typical fashion -- no damage done.